31.08.2024 09:37:21
|
IO Biotech's Phase 3 Trial Data Fails To Show Superiority In ORR For IO102-IO103 With KEYTRUDA
(RTTNews) - IO Biotech (IOBT) announced that the Independent Data Monitoring Committee found the data from the Pivotal Phase 3 Trial of IO102-IO103 in combination with KEYTRUDA (pembrolizumab) as a first-line treatment for advanced melanoma did not meet the criteria for declaring superiority in overall response rate or ORR.
However, the Independent Data Monitoring Committee or IDMC recommended continuation of the company's pivotal Phase 3 trial of its lead investigational therapeutic vaccine, IO102-IO103, following a per-protocol interim analysis. The trial is evaluating IO102-IO103 in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, as a first-line treatment for patients with unresectable or metastatic (advanced) melanoma.
Based on their review of the safety and efficacy data, the IDMC recommended that the trial continue without modifications and noted that no new safety signals were observed. The primary endpoint of progression-free survival (PFS) is projected to be reached in the first half of 2025.
The per-protocol interim analysis was performed one year after 225 patients were randomized in the trial.
IOBT closed Friday's regular trading at $1.50 down $0.04 or 2.60%. In the after-hours trading, the stock further dropped $0.19 or 12.67%.
For More Such Health News, visit rttnews.com.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
05.02.25 |
Starker Wochentag in New York: Dow Jones schlussendlich freundlich (finanzen.at) | |
05.02.25 |
Pluszeichen in New York: Dow Jones verbucht am Mittag Zuschläge (finanzen.at) | |
05.02.25 |
Börse New York in Rot: Dow Jones präsentiert sich zum Start leichter (finanzen.at) | |
04.02.25 |
Zuversicht in New York: S&P 500 zum Handelsende mit Kursplus (finanzen.at) | |
04.02.25 |
Gewinne in New York: Dow Jones schlussendlich im Plus (finanzen.at) | |
04.02.25 |
Merck & Co-Aktie zweistellig tiefer: Merck & Co erwartet 2025 möglichen Umsatzrückgang (dpa-AFX) | |
04.02.25 |
Optimismus in New York: So entwickelt sich der Dow Jones aktuell (finanzen.at) | |
04.02.25 |
S&P 500-Handel aktuell: S&P 500 nachmittags mit positivem Vorzeichen (finanzen.at) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
IO Biotech Inc Registered Shs | 0,93 | -2,72% | |
Merck Co. | 84,40 | -0,35% |